Mundipharma
Eva Zielonka is an accomplished professional with extensive experience in business operations and development within the pharmaceutical industry. Currently serving as the Director of Business Operations for Global Commercial Operations at Mundipharma since May 2017, Eva plays a pivotal role as an operational advisor to the Vice-President and Cluster General Manager across the Middle East, Africa, and Latin America. Previously, Eva held positions at Novartis, where significant contributions were made in growing biologic businesses and enhancing new product planning processes. Educational qualifications include an MBA from the University of Cape Town and other degrees in the sciences and business from prestigious institutions.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.